Bristol Myers Squibb (BMY) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $2.44.
- Bristol Myers Squibb's Debt to Equity fell 1953.9% to $2.44 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.44, marking a year-over-year decrease of 1953.9%. This contributed to the annual value of $2.44 for FY2025, which is 1953.9% down from last year.
- According to the latest figures from Q4 2025, Bristol Myers Squibb's Debt to Equity is $2.44, which was down 1953.9% from $2.63 recorded in Q3 2025.
- Over the past 5 years, Bristol Myers Squibb's Debt to Equity peaked at $3.36 during Q1 2024, and registered a low of $0.87 during Q4 2022.
- In the last 5 years, Bristol Myers Squibb's Debt to Equity had a median value of $1.29 in 2022 and averaged $1.85.
- As far as peak fluctuations go, Bristol Myers Squibb's Debt to Equity soared by 24799.36% in 2024, and later tumbled by 1953.9% in 2025.
- Quarter analysis of 5 years shows Bristol Myers Squibb's Debt to Equity stood at $1.0 in 2021, then decreased by 13.32% to $0.87 in 2022, then grew by 0.0% to $0.87 in 2023, then skyrocketed by 247.99% to $3.03 in 2024, then dropped by 19.54% to $2.44 in 2025.
- Its Debt to Equity stands at $2.44 for Q4 2025, versus $2.63 for Q3 2025 and $2.81 for Q2 2025.